Center for Scientific Review; Notice of Closed Meetings, 47758-47759 [2017-22140]
Download as PDF
<![CDATA[
47758
Federal Register / Vol. 82, No. 197 / Friday, October 13, 2017 / Notices
tube. The implant can extend through or
over the limbs. The implant and at least
a distal portion of the limbs can be
compressible into a delivery shape that
allows for advancement through the
lumen of a delivery catheter. When the
distal portion of the limbs move out of
the delivery catheter, the limbs and
implant can resiliently assume a loop
shape that is complementary to a shape
of a target around which the encircling
implant is to be placed. The limbs are
then retracted from along the implant to
leave the implant in the desired delivery
position. The delivery device can be
used to place encircling implants
around the heart or other targets, and
the implant can be tightened to exert
compressive force on the target.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive patent license
will be royalty bearing and may be
granted unless within fifteen (15) days
from the date of this published notice,
the NHLBI receives written evidence
and argument that establishes that the
grant of the license would not be
consistent with the requirements of 35
U.S.C. 209 and 37 CFR part 404.
Complete applications for a license in
the prospective field of use that are
timely filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive patent
license. Comments and objections
submitted to this notice will not be
made available for public inspection
and, to the extent permitted by law, will
not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: September 22, 2017.
Michael Shmilovich,
Senior Licensing and Patenting Manager,
National Heart, Lung, and Blood Institute,
Office of Technology Transfer and
Development.
[FR Doc. 2017–22157 Filed 10–12–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
VerDate Sep<11>2014
18:05 Oct 12, 2017
Jkt 244001
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: AIDS and Related
Research Integrated Review Group; AIDSassociated Opportunistic Infections and
Cancer Study Section.
Date: November 6, 2017.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Fairmont Washington, D.C.,
2401 M Street NW., Washington, DC 20037.
Contact Person: Eduardo A Montalvo,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5108,
MSC 7852, Bethesda, MD 20892, (301) 435–
1168, montalve@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; The BloodBrain Barrier, Neurovascular System and
CNS Therapeutics.
Date: November 7, 2017.
Time: 10:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Linda MacArthur, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4187,
Bethesda, MD 20892, 301–537–9986,
macarthurlh@csr.nih.gov.
Name of Committee: AIDS and Related
Research Integrated Review Group;
Behavioral and Social Consequences of HIV/
AIDS Study Section.
Date: November 8–9, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Admiral Fell Inn, 888 South
Broadway, Baltimore, MD 21231.
Contact Person: Mark P Rubert, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5218,
MSC 7852, Bethesda, MD 20892, 301–806–
6596, rubertm@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR Panel:
Decision Making and Aging in Alzheimer’s
Disease.
Date: November 8, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Kristin Kramer, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5205,
MSC 7846, Bethesda, MD 20892, (301) 437–
0911, kramerkm@csr.nih.gov.
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Brain and Spinal Cord Injury.
Date: November 8, 2017.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Boris P Sokolov, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5217A,
MSC 7846, Bethesda, MD 20892, 301–408–
9115, bsokolov@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Neurovirology and Neurodevelopmental
Aspects of Zika Virus Infection.
Date: November 8, 2017.
Time: 2:00 p.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Wei-Qin Zhao, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5181,
MSC 7846, Bethesda, MD 20892–7846, 301–
827–7238, zhaow@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Fellowships: Brain Disorders and Related
Neurosciences.
Date: November 9–10, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Residence Inn Bethesda Downtown,
7335 Wisconsin Ave, Bethesda, MD 20814.
Contact Person: Vilen A Movsesyan, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4040M,
MSC 7806, Bethesda, MD 20892, 301–402–
7278, movsesyanv@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR–17–
094: Maximizing Investigators Research
Award (R35).
Date: November 9–10, 2017.
Time: 8:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Doubletree Hotel Bethesda,
(Formerly Holiday Inn Select), 8120
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Dominique Lorang-Leins,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5108,
MSC 7766, Bethesda, MD 20892,
301.326.9721, Lorangd@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Immunobiology ExtremesAutoimmunity, Tolerance, and Cancer.
Date: November 9, 2017.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
E:\FR\FM\13OCN1.SGM
13OCN1
Federal Register / Vol. 82, No. 197 / Friday, October 13, 2017 / Notices
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: David B. Winter, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4204,
MSC 7812, Bethesda, MD 20892, 301–435–
1152, dwinter@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: October 6, 2017.
Anna Snouffer,
Deputy Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–22140 Filed 10–12–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent
License: Use of Pharmaceutical and
Biological Compositions Comprising
Gram-Negative Bacteria for the Topical
Treatment of Dermatological Diseases
and Dermatological Conditions
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Institute of
Allergy and Infectious Diseases, an
institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Commercialization
Patent License to practice the inventions
embodied in the Patents and Patent
Applications listed in the Summary
Information section of this notice to
Forte Biosciences, Inc. located in San
Diego, California.
DATES: Only written comments and/or
applications for a license which are
received by the National Institute of
Allergy and Infectious Diseases’
Technology Transfer and Intellectual
Property Office on or before October 30,
2017 will be considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
Exclusive Commercialization Patent
License should be directed to: David
Yang, Technology Transfer and
Patenting Specialist, Technology
Transfer and Intellectual Property
Office, National Institute of Allergy and
Infectious Diseases, National Institutes
of Health, 5601 Fishers Lane, Suite 6D,
Rockville, MD 20852–9804; Email:
asabaliauskas on DSKBBXCHB2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:05 Oct 12, 2017
Jkt 244001
yangp3@nih.gov; Telephone: (240) 627–
3413; Facsimile: (240) 627–3117.
SUPPLEMENTARY INFORMATION:
Intellectual Property
U.S. Provisional Application 62/
324,762, filed April 19, 2016, and PCT
Patent Application PCT/US2017/
028133, filed April 17, 2017, both
entitled ‘‘Use of Gram Negative Species
to Treat Atopic Dermatitis’’ [HHS Ref.
E–099–2016/0], and U.S. and foreign
patent applications claiming priority to
the aforementioned applications.
The patent rights in these inventions
have been assigned to the government of
the United States of America.
The prospective exclusive license
territory may be worldwide and the
field of use may be limited to the
following field of use: ‘‘Use of
pharmaceutical and biological
compositions comprising Gram-negative
bacteria for the topical treatment of
dermatological diseases and
dermatological conditions’’.
Atopic dermatitis (AD) is a common,
recurrent, chronic inflammatory skin
disease that is a cause of considerable
economic and social burden. It is one of
the most prevalent skin disorders,
affecting ∼25% of children in developed
and developing countries and is
expected to continue to escalate. This
increased rate of incidence has changed
the focus of research on AD toward
epidemiology, prevention, and
treatment.
The subject technology describes
pharmaceutical and biological
compositions comprising Gram-negative
bacteria that can be developed into a
topical treatment for atopic dermatitis
(AD), as well as methods and kits using
these compositions.
NIAID scientists have recently
identified probiotic strains of
Roseomonas mucosa bacteria that were
shown to be beneficial in a pre-clinical
mouse model of AD. With this
promising data, NIAID launched a phase
I/II clinical trial in March 2017 (link;
https://clinicaltrials.gov/ct2/show/
NCT03018275) and preliminary results
from this ongoing study show that the
technology may be highly effective at
treating and reducing the symptoms of
atopic dermatitis. If successfully
developed, this invention would be the
first live biotherapeutic product
approved by the FDA for the treatment
of AD.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
47759
Institute of Allergy and Infectious
Diseases receives written evidence and
argument that establishes that the grant
of the license would not be consistent
with the requirements of 35 U.S.C. 209
and 37 CFR part 404.
Complete applications for a license in
the prospective field of use that are filed
in response to this notice will be treated
as objections to the grant of the
contemplated Exclusive
Commercialization Patent License
Agreement. Comments and objections
submitted to this notice will not be
made available for public inspection
and, to the extent permitted by law, will
not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: October 4, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2017–22148 Filed 10–12–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Senior Executive Service Performance
Review Board
Office of the Secretary,
Department of Homeland Security
(DHS).
ACTION: Notice.
AGENCY:
This notice announces the
appointment of the members of the
Senior Executive Service (SES)
Performance Review Board (PRB) for
DHS. The purpose of the PRB is to view
and make recommendations concerning
proposed performance appraisals,
ratings, bonuses, pay adjustments, and
other appropriate personnel actions for
incumbents of SES, Senior Level and
Senior Professional positions of the
Department.
DATES: The PRB members’ terms begin
October 13, 2017.
FOR FURTHER INFORMATION CONTACT:
Elizabeth Haefeli, Office of the Chief
Human Capital Officer,
Elizabeth.Haefeli@hq.dhs.gov, or by
telephone (202) 357–8164.
SUPPLEMENTARY INFORMATION: Each
Federal agency is required to establish
one or more performance review boards
to make recommendations, as necessary,
in regard to the performance of senior
executives within the agency. 5 U.S.C.
4314(c). This notice announces the
appointment of the members of the PRB
for DHS. The purpose of the PRB is to
review and make recommendations
concerning proposed performance
SUMMARY:
E:\FR\FM\13OCN1.SGM
13OCN1
]]>Agencies
[Federal Register Volume 82, Number 197 (Friday, October 13, 2017)]
[Notices]
[Pages 47758-47759]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-22140]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: AIDS and Related Research Integrated Review
Group; AIDS-associated Opportunistic Infections and Cancer Study
Section.
Date: November 6, 2017.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: The Fairmont Washington, D.C., 2401 M Street NW.,
Washington, DC 20037.
Contact Person: Eduardo A Montalvo, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5108, MSC 7852, Bethesda, MD
20892, (301) 435-1168, montalve@csr.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; The Blood-Brain Barrier, Neurovascular System and CNS
Therapeutics.
Date: November 7, 2017.
Time: 10:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Linda MacArthur, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4187, Bethesda, MD 20892, 301-
537-9986, macarthurlh@csr.nih.gov.
Name of Committee: AIDS and Related Research Integrated Review
Group; Behavioral and Social Consequences of HIV/AIDS Study Section.
Date: November 8-9, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Admiral Fell Inn, 888 South Broadway, Baltimore, MD
21231.
Contact Person: Mark P Rubert, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 5218, MSC 7852, Bethesda, MD 20892, 301-806-
6596, rubertm@csr.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; PAR Panel: Decision Making and Aging in Alzheimer's Disease.
Date: November 8, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Kristin Kramer, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5205, MSC 7846, Bethesda, MD
20892, (301) 437-0911, kramerkm@csr.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Brain and Spinal Cord Injury.
Date: November 8, 2017.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Boris P Sokolov, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5217A, MSC 7846, Bethesda, MD
20892, 301-408-9115, bsokolov@csr.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Neurovirology and Neurodevelopmental Aspects of Zika Virus
Infection.
Date: November 8, 2017.
Time: 2:00 p.m. to 5:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Wei-Qin Zhao, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 5181, MSC 7846, Bethesda, MD 20892-7846, 301-
827-7238, zhaow@csr.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Fellowships: Brain Disorders and Related Neurosciences.
Date: November 9-10, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Residence Inn Bethesda Downtown, 7335 Wisconsin Ave,
Bethesda, MD 20814.
Contact Person: Vilen A Movsesyan, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4040M, MSC 7806, Bethesda, MD
20892, 301-402-7278, movsesyanv@csr.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; PAR-17-094: Maximizing Investigators Research Award (R35).
Date: November 9-10, 2017.
Time: 8:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Doubletree Hotel Bethesda, (Formerly Holiday Inn Select),
8120 Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Dominique Lorang-Leins, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5108, MSC 7766, Bethesda, MD
20892, 301.326.9721, Lorangd@mail.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Immunobiology Extremes- Autoimmunity,
Tolerance, and Cancer.
Date: November 9, 2017.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
[[Page 47759]]
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: David B. Winter, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4204, MSC 7812, Bethesda, MD
20892, 301-435-1152, dwinter@csr.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: October 6, 2017.
Anna Snouffer,
Deputy Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-22140 Filed 10-12-17; 8:45 am]
BILLING CODE 4140-01-P
